Mostrar el registro sencillo

dc.contributor.authorRando, Emanuele
dc.contributor.authorDelgado-Valverde, Mercedes
dc.contributor.authorGoikoetxea Aguirre, Josune
dc.contributor.authorGuio Carrión, Laura
dc.contributor.authorBlanco Vidal, María José
dc.contributor.authorBarrios Andrés, José Luis
dc.contributor.authorPérez Rodríguez, María Tersesa
dc.contributor.authorMartínez Lamas, Lucía
dc.contributor.authorArnaiz de las Revillas Almajano, Francisco
dc.contributor.authorArmiñanzas Castillo, Carlos 
dc.contributor.authorRuiz de Alegría Puig, Carlos
dc.contributor.authorJiménez Aguilar, Patricia
dc.contributor.authorMartínez-Rubio, María del Carmen
dc.contributor.authorSáez-Béjarf, Carmen
dc.contributor.authorCuevas, Carmen de las
dc.contributor.authorMartín-Aspas, Andrés
dc.contributor.authorGalán, Fátima
dc.contributor.authorYuste, José Ramón
dc.contributor.authorLeiva-León, Lucía
dc.contributor.authorBou, Germán
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-07-11T08:49:45Z
dc.date.available2025-07-11T08:49:45Z
dc.date.issued2025
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.otherPT17/0017/0012es_ES
dc.identifier.otherPT20/00123es_ES
dc.identifier.urihttps://hdl.handle.net/10902/36666
dc.description.abstractObjectives: We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial. Methods: We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure. Results: Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41). Conclusion: Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI.es_ES
dc.description.sponsorshipScren (Spanish Clinical research network, funded by Instituto de Salud Carlos III (PT17/0017/0012 and PT20/00123)).es_ES
dc.format.extent7 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights©2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceInternational Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 2025, 156, 107917es_ES
dc.subject.otherAntimicrobial stewardshipes_ES
dc.subject.otherOral switches_ES
dc.subject.otherEnterobacteraleses_ES
dc.subject.otherBloodstream infectiones_ES
dc.titleEffectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: a post hoc emulation trial of the SIMPLIFY triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.ijid.2025.107917es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.ijid.2025.107917
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

©2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND licenseExcepto si se señala otra cosa, la licencia del ítem se describe como ©2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license